​
​

CG Oncology Stock (NASDAQ:CGON)

ForecastRevenueOwnershipFinancialsChart
CG Oncology by TradingView

Previous Close

$33.21

52W Range

$25.77 - $50.23

50D Avg

$36.61

200D Avg

$36.42

Market Cap

$2.20B

Avg Vol (3M)

$654.30K

Beta

-

Div Yield

-

CGON Company Profile

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

-

Employees

61

IPO Date

-

Website

-

CGON Performance

CGON Financial Summary

Dec 23Dec 22Dec 21
Revenue$204.00K$191.00K$10.36M
Operating Income$-55.45M$-35.25M$-12.61M
Net Income$-48.61M$-35.44M$-12.84M
EBITDA$-55.43M$-35.23M$-12.60M
Basic EPS$-0.73$-0.53$-0.19
Diluted EPS$-0.73$-0.53$-0.19

Fiscal year ends in Dec 23 | Currency in USD